↓ Skip to main content

CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia

Overview of attention for article published in Stem Cell Research & Therapy, August 2017
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia
Published in
Stem Cell Research & Therapy, August 2017
DOI 10.1186/s13287-017-0620-4
Pubmed ID
Authors

Shihong Lu, Meili Ge, Yizhou Zheng, Jianping Li, Xiaoming Feng, Sizhou Feng, Jinbo Huang, Ying Feng, Donglin Yang, Jun Shi, Fang Chen, Zhongchao Han

Abstract

Acquired aplastic anemia (AA) is characterized by deficiency or dysfunction of the bone marrow (BM) microenvironment. However, little is known about the impairment of BM-derived mesenchymal stem cells (MSCs) in AA patients. We used Illumina HiSeqTM 2000 sequencing, quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry (FCM), and Western blotting to test the expression of CD106 gene (vascular cell adhesion molecule 1 (VCAM1)) and CD106 protein of BM-MSCs. Furthermore, we used hematoxylin and eosin (H&E) and histochemical staining analysis, immunofluorescence, and the formation of capillary-like structures to analyze capillary tube-like formation in vitro; we also used the Matrigel plug assay to test in vivo vasculogenesis, and an assay of colony forming units (CFUs) and colony-forming unit-megakaryocyte (CFU-MK) to detect the support function of MSCs in vitro. The in vivo engraftment of CD34(+) cells and MSCs in NOD/SCID mice was tested by FACS and survival assay; the expression of NF-κB was tested by NanoPro analysis and immunofluorescence. NF-κB-regulated CD106 gene (VCAM1) was confirmed by tumor necrosis factor alpha (TNF-α)-stimulated and lipopolysaccharide (LPS)-stimulated MSCs, blockade assay, and immunofluorescence. Here, we report that BM-MSCs from AA patients exhibited downregulation of the CD06 gene (VCAM1) and low expression of CD106 in vitro. Further analysis revealed that CD106(+) MSCs from both AA patients and healthy controls had increased potential for in vitro capillary tube-like formation and in vivo vasculogenesis compared with CD106(-) MSCs, and the results were similar when healthy MSCs were compared with AA MSCs. CD106(+) MSCs from both AA patients and healthy controls more strongly supported in vitro growth and in vivo engraftment of CD34(+) cells in NOD/SCID mice than CD106(-) MSCs, and similar results were obtained when healthy MSCs and AA MSCs were compared. The expression of NF-κB was decreased in AA MSCs, and NF-κB regulated the CD106 gene (VCAM1) which supported hematopoiesis. These results revealed the effect of CD106 and NF-κB in BM failure of AA.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 24%
Student > Master 4 11%
Researcher 4 11%
Student > Bachelor 4 11%
Other 2 5%
Other 5 13%
Unknown 10 26%
Readers by discipline Count As %
Medicine and Dentistry 9 24%
Agricultural and Biological Sciences 6 16%
Immunology and Microbiology 3 8%
Engineering 3 8%
Biochemistry, Genetics and Molecular Biology 2 5%
Other 4 11%
Unknown 11 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2017.
All research outputs
#17,910,703
of 22,996,001 outputs
Outputs from Stem Cell Research & Therapy
#1,595
of 2,429 outputs
Outputs of similar age
#227,604
of 317,441 outputs
Outputs of similar age from Stem Cell Research & Therapy
#33
of 48 outputs
Altmetric has tracked 22,996,001 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,429 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,441 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.